ACE2 and COVID-19: Although some experts suggest that ACE2-stimulating drugs increase the risk of severe coronavirus disease 2019 (COVID-19) [1], others recommend that patients should continue antihypertensive therapy because there is no clinical evidence to suggest that treatment with ACEi or ARBs should be discontinued in cases of COVID-19 infection [2].